This 2023 statement updates clinical guidance for homozygous familial
hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic …

This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …

Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial
infarction, stroke and peripheral arterial disease continue to be major causes of premature …

Abstract Purpose of Review Familial hypercholesterolemia (FH) is the most common genetic
metabolic disorder characterized by markedly elevated LDL-C levels from birth leading to …

Berberine (BBR) is an effective cholesterol-lowering drug. Although gut microbiota has been
implicated in the pharmacological activities of BBR, little evidence exists on the specific …

Current dyslipidemia management in patients with atherosclerotic cardiovascular disease
(ASCVD) is based on traditional serum lipids. Yet, there is some indication from basic …

Familial hypercholesterolaemia (FH) is under-recognized and under-treated in Europe
leading to significantly higher risk for premature heart disease in those affected. As treatment …

Summary Background The European Atherosclerosis Society Familial
Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for …

Familial hypercholesterolaemia (FH) is a common autosomal semi-dominant and highly
penetrant disorder of the low-density lipoprotein (LDL) receptor pathway, characterised by …

Primary hyperlipidemias include a heterogeneous set of monogenic and polygenic
conditions characterized by a strong family aggregation, severe forms of …